AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
pibrentasvir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals, hepatitis C Virus (HCV) NS5A inhibitors | 5244 | 1353900-92-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Pibrentasvir is an inhibitor of HCV NS5A, which is essential for viral RNA replication and virion assembly. The mechanism of action of pibrentasvir has been characterized based on cell culture antiviral activity and drug resistance mapping studies.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 4 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | GRK2,MAPK10,PDK1,PDK2,PDK4 | 5 | |||
| kinase-selectivity-class | PDK1 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 26, 2017 | EMA | AbbVie Deutschland GmbH & Co. KG | |
| Aug. 3, 2017 | FDA | ABBVIE INC | |
| Sept. 27, 2017 | PMDA | AbbVie GK |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AP57 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HCV infections |
| FDA MoA | N0000182138 | Cytochrome P450 1A2 Inhibitors |
| FDA MoA | N0000185503 | P-Glycoprotein Inhibitors |
| FDA MoA | N0000190107 | Organic Anion Transporting Polypeptide 1B1 Inhibitors |
| FDA MoA | N0000190108 | Organic Anion Transporting Polypeptide 1B3 Inhibitors |
| FDA MoA | N0000190113 | Breast Cancer Resistance Protein Inhibitors |
| FDA MoA | N0000190114 | Cytochrome P450 3A Inhibitors |
| FDA EPC | N0000191256 | Hepatitis C Virus NS5A Inhibitor |
| FDA MoA | N0000191272 | UGT1A1 Inhibitors |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
Related Drugs by ATC class:
J05AP Antivirals for treatment of HCV infections 18 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chronic hepatitis C | indication | 128302006 | |
| Compensated cirrhosis | indication | 371139006 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.04 | acidic |
| pKa2 | 11.64 | acidic |
| pKa3 | 12.69 | acidic |
| pKa4 | 13.29 | acidic |
| pKa5 | 5.17 | Basic |
| pKa6 | 4.56 | Basic |
| pKa7 | 1.2 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10028937 | June 10, 2030 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10028937 | June 10, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10028937 | June 10, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10039754 | June 10, 2030 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10039754 | June 10, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10039754 | June 10, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 10028937 | June 10, 2030 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 10028937 | June 10, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 10039754 | June 10, 2030 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 10039754 | June 10, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 9586978 | Nov. 6, 2030 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 9586978 | Nov. 6, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 9586978 | Nov. 6, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 9586978 | Nov. 6, 2030 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 9586978 | Nov. 6, 2030 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 8648037 | Jan. 19, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 8648037 | Jan. 19, 2032 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 8648037 | Jan. 19, 2032 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 8648037 | Jan. 19, 2032 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 8648037 | Jan. 19, 2032 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10286029 | March 14, 2034 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 10286029 | March 14, 2034 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 11484534 | March 14, 2034 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | 11484534 | March 14, 2034 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 10286029 | March 14, 2034 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | 10286029 | March 14, 2034 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | April 30, 2026 | TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1,2,3,4,5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A) |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | April 30, 2026 | TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), BUT NOT BOTH |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | Oct. 30, 2026 | PEDIATRIC EXCLUSIVITY |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | June 10, 2028 | FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), B |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | June 10, 2028 | TREATMENT OF ACUTE HEPATITIS C VIRUS (HCV) INFECTION IN ADULTS AND PEDIATRIC PATIENTS AGES 3 TO LESS THAN 18 YEARS OF AGE |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | June 10, 2028 | FOR TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS (CHILD-PUGH A); AND TREATMENT OF PEDIATRIC PATIENTS 3 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WEIGHING LESS THAN 45 KG WITH HCV GENOTYPE 1 INFECTION, WHO PREVIOUSLY HAVE BEEN TREATED WITH A REGIMEN CONTAINING AN HCV NS5A INHIBITOR OR AN NS3/4A PROTEASE INHIBITOR (PI), B |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | June 10, 2028 | TREATMENT OF ACUTE HEPATITIS C VIRUS (HCV) INFECTION IN ADULTS AND PEDIATRIC PATIENTS AGES 3 TO LESS THAN 18 YEARS OF AGE |
| 100MG;40MG | MAVYRET | ABBVIE | N209394 | Aug. 3, 2017 | RX | TABLET | ORAL | Dec. 10, 2028 | PEDIATRIC EXCLUSIVITY |
| 50MG/PACKET;20MG/PACKET | MAVYRET | ABBVIE | N215110 | June 10, 2021 | RX | PELLETS | ORAL | Dec. 10, 2028 | PEDIATRIC EXCLUSIVITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Nonstructural protein 5A | Unclassified | EC50 | 10.19 | CHEMBL | |||||
| Genome polyprotein [Cleaved into: Core protein p21 | Enzyme | EC50 | 9.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 2WU922TK3L | UNII |
| 4036872 | VANDF |
| C4519537 | UMLSCUI |
| CHEBI:755470 | CHEBI |
| CHEMBL3545123 | ChEMBL_ID |
| 58031952 | PUBCHEM_CID |
| DB13878 | DRUGBANK_ID |
| D10816 | KEGG_DRUG |
| 10260 | INN_ID |
| C000622691 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11268 | IUPHAR_LIGAND_ID |
| 736836002 | SNOMEDCT_US |
| 816102004 | SNOMEDCT_US |
| 33001 | MMSL |
| d08634 | MMSL |
| 017296 | NDDF |
| 1940636 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Mavyret | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-2600 | PELLET | 20 mg | ORAL | NDA | 34 sections |
| Mavyret | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0074-2625 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 34 sections |